Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1853371 | 0.94 | KMT2A (0.64) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL2401694 | 0.90 | KMT2A (0.70) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL5972005 | 0.90 | KMT2A (0.70) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL3623157 | 0.89 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CASP3 | |
| Glutarate SCHEMBL3623154 | 0.87 | KMT2A (0.52) | KMT2AEGFRFFAR4 | |
| SCHEMBL31378081 | 0.86 | KMT2A (0.59) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL5497609 | 0.86 | KMT2A (0.59) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL16476528 | 0.84 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL14759878 | 0.84 | KMT2A (0.60) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL12440444 | 0.84 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1225918-A2 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | Merck & Co., Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001028593-A2 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | MERCK & CO., INC. (US) | 2001-04-26 | — | — | WO | disclosed |